Labiotech.eu

News and Trends 2 Jun 2023

Faux filet: World’s first 3D-printed ready-to-cook fish produced

As biotechs come up with fascinating, new ways to cultivate food, Israel-based Steakholder Foods has created the first-ever 3D-printed fish filets. These ready-to-cook filets, which are developed from animal cells that are grown in laboratories, are obtained from the startup’s proprietary 3D bioprinters and customized bio-inks. Said to have the same taste and texture as […]

June 2, 2023 - 3 minutesmins - By Roohi Mariam Peter

Podcast 2 Jun 2023

Beyond Biotech podcast 48

BioInvent International AB, a Swedish biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, recently announced positive phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. BioInvent currently has four […]

June 2, 2023

News and Trends 2 Jun 2023

Scientists develop probe to push for new drug discoveries

A study by Loughborough University and the University of Oxford in the U.K. has led to the development of a small molecule probe that could deepen the understanding of a crucial cellular messenger and lead to the development of new therapeutic drugs. The research paper showcases the researchers’ innovative probe that binds to inositol pyrophosphate […]

June 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Jun 2023

New approach improves cancer treatment and minimizes side effects

Scientists at Tohoku University in Japan have discovered a new approach to improve the efficacy of immune checkpoint blockade (ICB) – a novel form of cancer treatment utilizing immune checkpoint inhibitors (ICIs) – while minimizing the associated side effects. They demonstrated that using ICIs to target tumor-positive lymph nodes generates a robust anti-tumor response against […]

June 2, 2023 - 2 minutesmins - By Jim Cornall

blood bleeding disorders von Willebrand disease

News and Trends 2 Jun 2023

von Willebrand disease treatment gets FDA orphan drug designation

The U.S. Food and Drug Administration (FDA) has granted Vega Therapeutics, Inc. orphan drug designation for its antibody therapy, VGA039, for the treatment of the rare bleeding disorder, von Willebrand disease (VWD). Vega Therapeutics is a clinical stage biotechnology company developing novel therapies for rare blood disorders. VGA039 is a first-in-class antibody therapy with a […]

June 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Jun 2023

Anocca raises $36.6M for large-scale development of cancer cell therapies

Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […]

June 2, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 1 Jun 2023

Five ophthalmology biotech companies to look out for

There are hundreds of different eye diseases, with some of the most common major eye diseases including age-related macular degeneration (AMD) – an age-related eye disease that can blur central vision – glaucoma – a condition where the optic nerve becomes damaged – and diabetic retinopathy (DR) – a complication of diabetes in which high […]

June 1, 2023 - 6 minutesmins - By Willow Shah-Neville

News and Trends 1 Jun 2023

Swiss researchers develop new class of antibiotics to fight resistant bacteria

Health professionals are in urgent need of new antibiotics to tackle resistant bacteria. Researchers at the University of Zurich (UZH), in Switzerland, and the company Spexis, have now modified the chemical structure of naturally occurring peptides to develop antimicrobial molecules that bind to novel targets in the bacteria’s metabolism. Each year, more than five million […]

June 1, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […]

June 1, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

ElevateBio raises $401M for cell and gene therapies

ElevateBio, LLC (ElevateBio), a technology-driven company focused on cell and gene therapies, has closed its $401 million Series D financing. “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled to welcome Khalil to our […]

June 1, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Fighting obesity with gene therapy

Scientists from the University of Barcelona in Spain and the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBERobn) have designed a strategy to fight obesity and diabetes in mice through ex vivo gene therapy. The technique consists of implanting cells that have been manipulated and transformed in order to treat a disease. This […]

June 1, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Lonza boosts ADC portfolio with Synaffix acquisition

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs). While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which […]

June 1, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Faux filet: World’s first 3D-printed ready-to-cook fish produced

Beyond Biotech podcast 48

Scientists develop probe to push for new drug discoveries

New approach improves cancer treatment and minimizes side effects

von Willebrand disease treatment gets FDA orphan drug designation

Anocca raises $36.6M for large-scale development of cancer cell therapies

Five ophthalmology biotech companies to look out for

Swiss researchers develop new class of antibiotics to fight resistant bacteria

Sanofi drug reduces disease activity in relapsing MS

ElevateBio raises $401M for cell and gene therapies

Fighting obesity with gene therapy

Lonza boosts ADC portfolio with Synaffix acquisition

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!